HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, today announced
that Dr. Martin Tallman, Chief of
Leukemia for Memorial Sloan Kettering Cancer Center has joined the
Company's Science Advisory Board (SAB).
"The emergence of Annamycin as an important next generation
anthracycline for the treatment of relapsed or refractory acute
myeloid leukemia is now being recognized at the highest levels of
leukemia research," commented Walter
Klemp, Moleculin's Chairman and CEO. "We are honored to have
Dr. Martin Tallman join the other
distinguished members of our SAB."
Dr. Martin Tallman added: "There
continues to be a significant unmet need for effective second-line
induction therapies in AML. Annamycin's apparent lack of
cardiotoxicity and demonstrated ability to avoid multi-drug
resistance mechanisms make it a promising drug candidate. I
look forward to helping the Moleculin team push this forward in its
clinical trials."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and AML, and WP1220, an analog to
WP1066, for the topical treatment of cutaneous T-cell lymphoma.
Moleculin Biotech is also engaged in preclinical development of
additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Annamycin to
show safety and efficacy in patients. Although Moleculin Biotech
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Moleculin Biotech
has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts
Joe Dorame,
Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original
content:http://www.prnewswire.com/news-releases/moleculin-announces-memorial-sloan-kettering-chief-of-leukemia-joins-science-advisory-board-300813695.html
SOURCE Moleculin Biotech, Inc.